APSR2026-69

Yes
Late-Breaking
Submitted
Oral Presentation
AO03-002
 
 
https://storage.unitedwebnetwork.com/files/1285/1202846-46903-APSR26_Oral 王丹_426271.pptx
Format: PPTX Only
 
Format: PDF Only
07. COPD
1

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Dan Wang * The First Affiliated Hospital of Chongqing Medical University Department of Respiratory and Critical Care Medicine Chongqing China
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Dan
Wang
wangdan@hospital.cqmu.edu.cn
+8613488947017
31-40
China
Original Research
CD16/CD163 Bispecific Antibody–Guided PPARγ LNPs Reprogram Heterogeneous Alveolar Macrophages for the Reversal of Pathological Airway Remodeling
Maximum 25 words
Abstract Content
Alveolar macrophage (AM) polarization imbalance is a key driver of pathological airway remodeling in chronic respiratory diseases such as COPD and asthma(Lazarov T et al. Nature 2023;618:698-707). This study aimed to establish PPARγ as a central regulator of AM polarization homeostasis and to develop a novel targeted intervention system for precise therapeutic modulation.
Multi-cohort clinical samples(30 controls , 23 Asthma and 24 COPD patients)and diverse animal models(wild type, TLR−/− ,PPAR-/-and IL-4−/− mice were stimulated with CS / HDM)were analyzed. A CD16/CD163 bispecific antibody (BsAb) was engineered and conjugated to PPARγ mRNA-loaded lipid nanoparticles (BsAb-LNPs) via Kih/CrossMab format. Targeting specificity and therapeutic effects were evaluated in both in vitro and in vivo.
PPARγ downregulation in AMs drove polarization dysregulation, amplifying M1 activity (e.g., TNF-α increased 4.3-fold) while suppressing M2 function (e.g., IL-10 decreased 2.4-fold). BsAb-LNPs demonstrated highly selective and prolonged (>72 h) retention in AMs, activated the AMPK–mTOR axis, driving lipid metabolic reprogramming (↑ CPT1A, SIRT1, PGC-1α), suppressing glycolysis (↓ GLUT1, HIF-1α), and enhancing mitochondrial bioenergetics. Notably, the BsAb was found to physically bridge M1 and M2 AMs, forming immune-synapse-like structures. In murine models of pathological airway remodeling (CS/HDM), BsAb-LNPs rebalanced AM populations (↓ CD86⁺, ↑ CD206⁺), and attenuated airway remodeling. Cellular co-localization confirmed precise PPARγ expression restricted predominantly to AMs, supporting targeted delivery and biosafety.
This work presents a BsAb-guided metabolic reprogramming strategy for precise AM modulation, offering a novel targeted therapy for refractory airway remodeling.
 
 
 
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1202846-37089-Figure_364517.jpg
JPG or JPEG or PNG format ONLY
Alveolar Macrophages, Bispecific Antibody, Airway Remodeling
maximum 3 keywords and no abbreviations, separated by commas
none
246